Infants and young children are at increased risk for respiratory syncytial virus (RSV) infections because of their maturing immune system and lack of prior exposure to RSV. This study will help us learn if a new vaccine is safe and can help infants produce antibodies which may help fight off RSV.

Your child may qualify if they are:

  • 6 months to 22 months of age
  • Born at full term of pregnancy (≥ 37 weeks)
  • Healthy as determined by medical evaluation including medical history
  • Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.

Share This Trial, Choose Your Platform!